[New approval: Avelumab - maintenance therapy for advanced or metastatic urothelial carcinoma]

Iona Campo Le Brun; Marc-Antoine Benderra

doi:10.1016/j.bulcan.2021.04.012

[New approval: Avelumab - maintenance therapy for advanced or metastatic urothelial carcinoma]

Bull Cancer. 2021 Sep;108(9):784-786. doi: 10.1016/j.bulcan.2021.04.012. Epub 2021 Jul 28.

[Article in French]

Authors

Iona Campo Le Brun¹, Marc-Antoine Benderra²

Affiliations

¹ Groupe hospitalier Henri-Mondor, hôpitaux universitaires Henri-Mondor, 1, rue Gustave-Eiffel, 94000 Créteil, France. Electronic address: iona.campolebrun@gmail.com.
² Hôpital Tenon oncologie médicale, 4, rue de la Chine, 75020 Paris, France.

PMID: 34332742
DOI: 10.1016/j.bulcan.2021.04.012

No abstract available

Keywords: Advanced; Avelumab; Bladder cancer; Cancer de vessie; Carcinome urothélial; Localement avancé; Metastatic; Métastatique; Urothelial carcinoma.

Publication types

News

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Transitional Cell / drug therapy*
Carcinoma, Transitional Cell / secondary
Clinical Trials, Phase III as Topic
Drug Approval*
Humans
Maintenance Chemotherapy*
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / pathology

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
avelumab